Upstream Bio, Inc. (NASDAQ:UPB) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Upstream Bio, Inc. (NASDAQ:UPB) have been given a consensus rating of “Moderate Buy” by the six brokerages that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have issued a buy recommendation on the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $38.20.

UPB has been the topic of a number of research reports. Weiss Ratings downgraded Upstream Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 6th. Evercore cut Upstream Bio from an “outperform” rating to an “in-line” rating and set a $15.00 target price for the company. in a report on Friday, March 27th. HC Wainwright started coverage on Upstream Bio in a report on Wednesday, June 3rd. They issued a “buy” rating and a $36.00 target price for the company. Wall Street Zen cut Upstream Bio from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. Finally, Mizuho dropped their target price on Upstream Bio from $51.00 to $50.00 and set an “outperform” rating for the company in a report on Thursday, May 14th.

Hedge Funds Weigh In On Upstream Bio

A number of institutional investors and hedge funds have recently modified their holdings of UPB. GF Fund Management CO. LTD. purchased a new position in shares of Upstream Bio in the 4th quarter worth approximately $29,000. Torren Management LLC purchased a new position in Upstream Bio during the 4th quarter valued at $30,000. BNP Paribas Financial Markets boosted its holdings in Upstream Bio by 229.8% during the 2nd quarter. BNP Paribas Financial Markets now owns 3,097 shares of the company’s stock valued at $34,000 after acquiring an additional 2,158 shares during the period. Legal & General Group Plc boosted its holdings in Upstream Bio by 83.0% during the 2nd quarter. Legal & General Group Plc now owns 3,174 shares of the company’s stock valued at $35,000 after acquiring an additional 1,440 shares during the period. Finally, Empowered Funds LLC purchased a new position in Upstream Bio during the 4th quarter valued at $45,000.

Upstream Bio Price Performance

NASDAQ:UPB opened at $6.28 on Thursday. Upstream Bio has a 1 year low of $6.25 and a 1 year high of $33.68. The stock’s 50 day simple moving average is $8.90 and its two-hundred day simple moving average is $17.05. The company has a market cap of $341.76 million, a price-to-earnings ratio of -2.16 and a beta of 1.10.

Upstream Bio (NASDAQ:UPB) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.02). Upstream Bio had a negative return on equity of 43.82% and a negative net margin of 4,718.96%.The firm had revenue of $1.03 million during the quarter, compared to the consensus estimate of $1.03 million. As a group, analysts anticipate that Upstream Bio will post -2.99 EPS for the current year.

About Upstream Bio

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.